Table 1 – Demographic characteristics in 81 subjects.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Patients with:</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Proven or Probable IPA</td>
<td>No IPA</td>
</tr>
<tr>
<td><strong>Sex:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>7</td>
<td>42</td>
</tr>
<tr>
<td>Female</td>
<td>6</td>
<td>26</td>
</tr>
<tr>
<td><strong>Age (years):</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>60.91</td>
<td>50.40</td>
</tr>
<tr>
<td>Range</td>
<td>37.09 – 73.39</td>
<td>17.97 – 72.45</td>
</tr>
<tr>
<td><strong>Transplant type:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allogeneic</td>
<td>6</td>
<td>40</td>
</tr>
<tr>
<td>Autologous</td>
<td>2</td>
<td>12</td>
</tr>
<tr>
<td>Non-Transplant</td>
<td>5</td>
<td>16</td>
</tr>
<tr>
<td><strong>Underlying disease:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALL (Acute Lymphoblastic Leukemia)</td>
<td>0</td>
<td>8</td>
</tr>
<tr>
<td>AML (Acute Myeloid Leukemia)</td>
<td>4</td>
<td>12</td>
</tr>
<tr>
<td>AMM (Agnogenic Myeloid Metaplasia)</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>AMML (Acute Myelomonocytic Leukemia)</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>CLL (Chronic Lymphocytic Leukemia)</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>CML (Chronic Myeloid Leukemia)</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td>HD (Hodgkin's Disease)</td>
<td>1</td>
<td>6</td>
</tr>
<tr>
<td>NHL (Non Hodgkin's Lymphoma)</td>
<td>1</td>
<td>8</td>
</tr>
<tr>
<td>MM (Multiple Myeloma)</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>RA (Refractory Anemia)</td>
<td>1</td>
<td>6</td>
</tr>
<tr>
<td>Other</td>
<td>2</td>
<td>8</td>
</tr>
</tbody>
</table>